Latest Articles

Publication Date
ACR-368 OncoSignature Assay Receives FDA Breakthrough Device Designation for Endometrial Cancer - Pharmacy Times

ACR-368 OncoSignature Assay Receives FDA Breakthrough Device Designation for Endometrial Cancer Pharmacy Times

Published: Feb. 10, 2025, 2:34 p.m.
SMARCA4-deficient Undifferentiated Carcinoma Co-existing with Primary Endometrial Gastric (or Gastrointestinal) -Type Carcinoma:A Case Report - Frontiers

SMARCA4-deficient Undifferentiated Carcinoma Co-existing with Primary Endometrial Gastric (or Gastrointestinal) -Type Carcinoma:A Case Report Frontiers

Published: Feb. 10, 2025, 2:08 p.m.
FDA Grants Breakthrough Status to Endometrial Cancer Assay - www.oncnursingnews.com/

FDA Grants Breakthrough Status to Endometrial Cancer Assay www.oncnursingnews.com/

Published: Feb. 9, 2025, 3:01 p.m.
Inhibition of lanosterol synthase linking with MAPK/JNK signaling pathway suppresses endometrial cancer - Nature.com

Inhibition of lanosterol synthase linking with MAPK/JNK signaling pathway suppresses endometrial cancer Nature.com

Published: Feb. 8, 2025, 1:17 p.m.
Molecular characterization of mixed-histology endometrial carcinoma provides prognostic and therapeutic value over morphologic findings - Nature.com

Molecular characterization of mixed-histology endometrial carcinoma provides prognostic and therapeutic value over morphologic findings Nature.com

Published: Feb. 8, 2025, 11:59 a.m.
Long-term risk of endometrial cancer after assisted reproductive technology.

What is the risk of endometrial cancer after long-term follow-up in women treated with ART between 1983 and 2001 compared with women in the general population and subfertile women who …

Published: Feb. 7, 2025, midnight
GLP1R Modulates Ferroptosis and Promotes Endometrial Cancer Progression: Insights from AN3CA Cell Study - Medical Dialogues

GLP1R Modulates Ferroptosis and Promotes Endometrial Cancer Progression: Insights from AN3CA Cell Study Medical Dialogues

Published: Feb. 6, 2025, 2:45 p.m.
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay - Medical Device Network

FDA grants breakthrough designation for Acrivon’s endometrial cancer assay Medical Device Network

Published: Feb. 6, 2025, 10 a.m.
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay - Yahoo! Voices

FDA grants breakthrough designation for Acrivon’s endometrial cancer assay Yahoo! Voices

Published: Feb. 6, 2025, 9:54 a.m.
Non-inferiority study to compare the efficacy of relugolix with dienogest for endometriosis-associated pain and usefulness of administering relugolix prior to dienogest (READY study): study protocol for a multicenter randomized controlled study.

Endometriosis presents as endometrial tissue growths outside the uterine cavity with its major symptoms including dysmenorrhea and infertility. Progestin preparations, such as dienogest, are the first-line therapy for endometriosis symptoms, …

Published: Feb. 6, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!